Xbrane Biopharma AB (publ) (STO:XBRANE)

Market Cap	212.73M -16.2%
Revenue (ttm)	259.70M +74.1%
Net Income	100.52M
EPS	4.51
Shares Out	20.61M
PE Ratio	2.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,231
Average Volume	53,528
Open	9.95
Previous Close	9.91
Day's Range	9.92 - 10.90
52-Week Range	8.30 - 38.25
Beta	0.79
RSI	43.27
Earnings Date	Feb 20, 2026

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial s...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 26
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XBRANE

Financial Performance

In 2024, Xbrane Biopharma AB's revenue was 198.72 million, a decrease of -16.76% compared to the previous year's 238.73 million. Losses were -266.22 million, -31.42% less than in 2023.